



01-24-04

Docket No: AM101193
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: **Chengjin M. HUANG**
Application No.: **10/648,667** Group Art No.: **1632**
Filed: **August 26, 2003** Examiner: **to be assigned**
For: **MONOCLONAL ANTIBODY SPECIFIC FOR AN EPITOPE OF
INACTIVATED FELINE IMMUNODEFICIENCY-ENCODED
GLYCOPROTEIN**
Confirmation No.: **3920**
Customer Number: **25291**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
b. ☒ is filed before the mailing date of a first Office Action on the merits.
c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV 311411243 us addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

January 23, 2004
Date

Cecilia Chessell
Cecilia Chessell

3. ☒ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies
- a. ☒ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.
- ☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.
- ☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.
Prior application is Application Number _____, filed on _____ of _____ for _____

For the sake of good order also submitted herewith is a copy (which is a marked copy in red ink) of the PTO-1449 previously submitted August 26, 2003; and item 3 does not apply.


- ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☒ Fees
☒ Fee for filing under 37 CFR 1.97(c) or (d) Fee: **\$180.00**

Method of Payment of Fees:
Charge **Deposit Account No. 01-1425** in the amount of **\$180.00**
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:
Credit any overpayment and charge any underpayment to Deposit Account No.
01-1425.



Adley F. Mandel
Attorney for Applicants
Reg. No. 26,942

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (973) 660-7659

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT January 23, 2004 (use as many sheets as necessary)		O I P T E JAN 23 2004 PATENTS & TRADEMARKS		Complete if Known	
		Application Number		10/648,667	
		Filing Date		August 26, 2003	
		First Named Inventor		Chengjin M. Huang	
		Group Art Unit		1632	
		Examiner Name		to be assigned	
Sheet	1	of	1	Attorney Docket Number	AM101193

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	6,107,077		Yamamoto	08-22-2000	
	2.	6,376,236	B1	Chiron Corporation	04-23-2002	
	3.	6,383,765	B1	Idexx Corporation	05-07-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	4.	PCT	WO 94/02613		Pitman-Moore Inc	02-03-1994		<input type="checkbox"/>
	5.	PCT	WO 94/20622		Akzo Nobel N.V.	09-15-1994		<input type="checkbox"/>
	6.	PCT	WO 92/15684		Cambridge Biotech Corp	09-17-1992		<input type="checkbox"/>
	7.	PCT	WO 90/06510		Idexx Corp	06-14-1990		<input type="checkbox"/>
	8.	EP	WO 997 529	A2	Pfizer Products Inc	05-03-2000		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	9.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT January 23, 2004 (use as many sheets as necessary)			Complete if Known		
			Application Number	10/648,667	
			Filing Date	August 26, 2003	
			First Named Inventor	Chengjin M. Huang	
			Group Art Unit	1632	
Examiner Name	to be assigned				
Sheet	1	of	1	Attorney Docket Number	AM101193

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	6,107,077		Yamamoto	08-22-2000	
	2.	6,376,236	B1	Chiron Corporation	04-23-2002	
	3.	6,383,765	B1	Idexx Corporation	05-07-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	4.	PCT	WO 94/02613		Pitman-Moore Inc	02-03-1994		<input type="checkbox"/>
	5.	PCT	WO 94/20622		Akzo Nobel N.V.	09-15-1994		<input type="checkbox"/>
	6.	PCT	WO 92/15684		Cambridge Biotech Corp	09-17-1992		<input type="checkbox"/>
	7.	PCT	WO 90/06510		Idexx Corp	06-14-1990		<input type="checkbox"/>
	8.	EP	WO 997 529	A2	Pfizer Products Inc	05-03-2000		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	9.		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number		to be assigned
			Filing Date		
			First Named Inventor		Chengjin M. HUANG
			Group Art Unit		to be assigned
Examiner Name			to be assigned		
Attorney Docket Number			AM 101193		
Sheet	1	of			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,177,014		O'Connor et al.	01-05-1993	
	2.	5,219,725		O'Connor et al.	06-15-1993	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	3.							<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. .	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	4.	BENDINELLI <i>et al.</i> , Feline Immunodeficiency Virus: an Interesting Model for AIDS Studies and an Important Cat Pathogen, Clinical Microbiology Review 8:, 1995, pp 87-112.		<input type="checkbox"/>
	5.	PANCINO <i>et al.</i> , Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties, Virology 206: pp 796-806.		<input type="checkbox"/>
	6.	PEDERSON <i>et al.</i> , Isolation of a T-lymphotropic lentivirus from domestic cats with immunodeficiency-like syndrome, Science 235: 1987, pp 790-793.		<input type="checkbox"/>

COPY

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.